|
1
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douaiher J, Ravipati A, Grams B, Chowdhury
S, Alatise O and Are C: Colorectal cancer-global burden, trends,
and geographical variations. J Surg Oncol. 115:619–630. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lefkowitz RJ and Shenoy SK: Transduction
of receptor signals by beta-arrestins. Science. 308:512–517. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luttrell LM and Lefkowitz RJ: The role of
beta-arrestins in the termination and transduction of
G-protein-coupled receptor signals. J Cell Sci. 115:455–465.
2002.PubMed/NCBI
|
|
7
|
Lefkowitz RJ, Rajagopal K and Whalen EJ:
New roles for beta-arrestins in cell signaling: Not just for
seven-transmembrane receptors. Mol Cell. 24:643–652. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barki-Harrington L and Rockman HA:
Beta-arrestins: Multifunctional cellular mediators. Physiology.
23:17–22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sobolesky PM and Moussa O: The role of
β-arrestins in cancer. Prog Mol Biol Transl Sci. 118:395–411. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu S, Wang D, Wu J, Jin J, Wei W and Sun
W: Involvement of β-arrestins in cancer progression. Mol Biol Rep.
40:1065–1071. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fereshteh M, Ito T, Kovacs JJ, Zhao C,
Kwon HY, Tornini V, Konuma T, Chen M, Lefkowitz RJ and Reya T:
β-Arrestin2 mediates the initiation and progression of myeloid
leukemia. Proc Natl Acad Sci USA. 109:12532–12537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bonnans C, Flacelière M, Grillet F, Dantec
C, Desvignes JP, Pannequin J, Severac D, Dubois E, Bibeau F,
Escriou V, et al: Essential requirement for β-arrestin2 in mouse
intestinal tumors with elevated Wnt signaling. Proc Natl Acad Sci
USA. 109:3047–3052. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duan X, Kong Z, Liu Y, Zeng Z, Li S, Wu W,
Ji W, Yang B, Zhao Z and Zeng G: β-Arrestin2 contributes to cell
viability and proliferation via the down-regulation of FOXO1 in
castration-resistant prostate cancer. J Cell Physiol.
230:2371–2381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Raghuwanshi SK, Nasser MW, Chen X,
Strieter RM and Richardson RM: Depletion of beta-arrestin-2
promotes tumor growth and angiogenesis in a murine model of lung
cancer. J Immunol. 180:5699–5706. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun WY, Hu SS, Wu JJ, Huang Q, Ma Y, Wang
QT, Chen JY and Wei W: Down-regulation of β-arrestin2 promotes
tumour invasion and indicates poor prognosis of hepatocellular
carcinoma. Sci Rep. 6:356092016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goertzen CG, Dragan M, Turley E, Babwah AV
and Bhattacharya M: KISS1R signaling promotes invadopodia formation
in human breast cancer cell via β-arrestin2/ERK. Cell Signal.
28:165–176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Z, Tian H, Jiang J, Yang Y, Tan S, Lin
X, Liu H and Wu B: β-Arrestin-2 modulates radiation-induced
intestinal crypt progenitor/stem cell injury. Cell Death Differ.
23:1529–1541. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jing X, Zhang H, Hu J, Su P, Zhang W, Jia
M, Cheng H, Li W and Zhou G: β-arrestin 2 is associated with
multidrug resistance in breast cancer cells through regulating MDR1
gene expression. Int J Clin Exp Pathol. 8:1354–1363.
2015.PubMed/NCBI
|
|
19
|
DeWire SM, Ahn S, Lefkowitz RJ and Shenoy
SK: Beta-arrestins and cell signaling. Annu Rev Physiol.
69:483–510. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li TT, Alemayehu M, Aziziyeh AI, Pape C,
Pampillo M, Postovit LM, Mills GB, Babwah AV and Bhattacharya M:
Beta-arrestin/Ral signaling regulates lysophosphatidic
acid-mediated migration and invasion of human breast tumor cells.
Mol Cancer Res. 7:1064–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Z, Tong W, Tan Z, Wang S and Lin P: The
clinical significance of β-arrestin 2 expression in the serum of
non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi.
14:497–501. 2011.(In Chinese). PubMed/NCBI
|
|
22
|
Alemayehu M, Dragan M, Pape C, Siddiqui I,
Sacks DB, Di Guglielmo GM, Babwah AV and Bhattacharya M:
β-Arrestin2 regulates lysophosphatidic acid-induced human breast
tumor cell migration and invasion via Rap1 and IQGAP1. PLoS One.
8:e561742013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma D and Parameswaran N: Multifaceted
role of β-arrestins in inflammation and disease. Genes Immun.
16:499–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Revankar CM, Vines CM, Cimino DF and
Prossnitz ER: Arrestins block G protein-coupled receptor-mediated
apoptosis. J Biol Chem. 279:24578–24584. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ahn S, Kim J, Hara MR, Ren XR and
Lefkowitz RJ: {beta}-Arrestin-2 mediates anti-apoptotic signaling
through regulation of BAD phosphorylation. J Biol Chem.
284:8855–8865. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang P, Gao H, Ni Y, Wang B, Wu Y, Ji L,
Qin L, Ma L and Pei G: Beta-arrestin 2 functions as a
G-protein-coupled receptor-activated regulator of oncoprotein Mdm2.
J Biol Chem. 278:6363–6370. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luan B, Zhang Z, Wu Y, Kang J and Pei G:
Beta-arrestin2 functions as a phosphorylation-regulated suppressor
of UV-induced NF-kappaB activation. EMBO J. 24:4237–4246. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun X, Zhang Y, Wang J, Wei L, Li H,
Hanley G, Zhao M, Li Y and Yin D: Beta-arrestin 2 modulates
resveratrol-induced apoptosis and regulation of Akt/GSK3β pathways.
Biochim Biophys Acta. 1800:912–918. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zeng LX, Tao J, Liu HL, Tan SW, Yang YD,
Peng XJ, Liu ZH, Jiang J and Wu B: β-Arrestin2 encourages
inflammation-induced epithelial apoptosis through ER stress/PUMA in
colitis. Mucosal Immunol. 8:683–695. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang F, Liu J, Fu H, Wang J, Li F, Yue H,
Li W, Zhao J and Yin D: GSK-3β promotes PA-induced apoptosis
through changing β-arrestin 2 nucleus location in H9c2
cardiomyocytes. Apoptosis. 21:1045–1055. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oya M, Takayanagi A, Horiguchi A, Mizuno
R, Ohtsubo M, Marumo K, Shimizu N and Murai M: Increased nuclear
factor-kappa B activation is related to the tumor development of
renal cell carcinoma. Carcinogenesis. 24:377–384. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lind DS, Hochwald SN, Malaty J, Rekkas S,
Hebig P, Mishra G, Moldawer LL, Copeland EM III and Mackay S:
Nuclear factor-kappa B is upregulated in colorectal cancer.
Surgery. 130:363–369. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lessard L, Mes-Masson AM, Lamarre L, Wall
L, Lattouf JB and Saad F: NF-kappa B nuclear localization and its
prognostic significance in prostate cancer. BJU Int. 91:417–420.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Camp ER, Li J, Minnich DJ, Brank A,
Moldawer LL, MacKay SL and Hochwald SN: Inducible nuclear
factor-kappaB activation contributes to chemotherapy resistance in
gastric cancer. J Am Coll Surg. 199:249–258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Körber MI, Klingenbrunner S, Bartsch R,
Steger GG and Mader RM: NF-κB addiction and resistance to
5-fluorouracil in a multi-stage colon carcinoma model. Int J Clin
Pharmacol Ther. 51:35–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Endo F, Nishizuka SS, Kume K, Ishida K,
Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K and Wakabayashi G: A
compensatory role of NF-κB to p53 in response to 5-FU-based
chemotherapy for gastric cancer cell lines. PLoS One. 9:e901552014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kwon OH, Kim JH, Kim SY and Kim YS:
TWEAK/Fn14 signaling mediates gastric cancer cell resistance to
5-fluorouracil via NF-κB activation. Int J Oncol. 44:583–590. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shakibaei M, Mobasheri A, Lueders C, Busch
F, Shayan P and Goel A: Curcumin enhances the effect of
chemotherapy against colorectal cancer cells by inhibition of NF-κB
and Src protein kinase signaling pathways. PLoS One. 8:e572182013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu B, Guo X, Mathew S, Armesilla AL,
Cassidy J, Darling JL and Wang W: Triptolide simultaneously induces
reactive oxygen species, inhibits NF-kappaB activity and sensitizes
5-fluorouracil in colorectal cancer cell lines. Cancer Lett.
291:200–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B
and Pei G: Identification of beta-arrestin2 as a G protein-coupled
receptor-stimulated regulator of NF-kappaB pathways. Mol Cell.
14:303–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Tang Y, Teng L, Wu Y, Zhao X and
Pei G: Association of beta-arrestin and TRAF6 negatively regulates
Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol.
7:139–147. 2006. View
Article : Google Scholar : PubMed/NCBI
|
